Podcasts about Lung cancer

Simple breath test could help identify lung cancer Breath test shows promise for identifying cancerous lung nodules Contact the Show: coolstuffdailypodcast@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Recorded at the 2026 IASLC World Conference on Lung Cancer in Seoul, this special Nurse Practitioner takeover episode looks at key developments in small cell lung cancer, antibody-drug conjugates, and lung cancer screening — with a focus on what APPs can take back to the clinic. Laura Macke, Stephanie McDonald, and Dr. Mary Pasquinelli discuss the studies and advances that caught their attention, including how these developments will affect patient conversations, treatment decisions, and the day-to-day work of APPs. Guests: Laura A. Macke, MS, FNP-C, AOCNP Nurse Practitioner Medstar Georgetown Cancer Institute Washington, DC Stephanie McDonald, MSN, FNP-BC, AOCNP Thoracic Oncology Nurse Practitioner Dana-Farber Cancer Institute Boston, MA Mary Pasquinelli, DNP, APRN, CTTS Lead Nurse Practitioner and Director of the Lung Screening Program University of Illinois Chicago

This week, Bobbi Conner talks with MUSC's Dr. Mariam Alexander about lung cancer in never-smokers.

HOST:  Hildy Grossman    CO-HOST:  Jordan Rich GUESTS:   Melina Marmarelis, MD    What if the secret to defeating lung cancer is already hidden inside our own cells? In this episode of Backstage @ Upstage, we explore the cutting edge of cancer care and how tiny biological clues are completely revolutionizing how we detect, understand, and treat lung cancer. We are joined by Dr. Melina Marmarelis, a leading thoracic oncologist and researcher at Penn Medicine (University of Pennsylvania). Dr. Marmarelis breaks down the vital role of biomarker testing and introduces us to the future of precision medicine: Next-Generation Sequencing. Discover how oncology is moving away from traditional, “one-size-fits-all” therapies toward hyper-customized treatment plans tailored to every individual patient—and how Artificial Intelligence is stepping in to analyze massive amounts of complex medical data to make it all possible. Tune in to discover the future of biomarker testing and how science, technology, and precision medicine are changing the outlook of lung cancer care to come!

National Comprehensive Cancer Network Guidelines for Lung Cancer & Managed Care On this episode host Steve Kheloussi, PharmD, principal consultant with Kheloussi Consulting and a managed care pharmacist, is joined by Tianyi Wang, consultant at Omnicom Health Market Access, and Irvin Molina, PharmD, BCOP, director of clinical pharmacy at IPD Analytics and a board-certified oncology pharmacist, to explore how National Comprehensive Cancer Network (NCCN) guidelines influence payer policy and patient access in non-small cell lung cancer (NSCLC).

The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Marie Drösslerová moderates a discussion in Czech about breakthrough advances in thoracic oncology presented at the conference with Dr. Fernando Casas Mendez and Dr. Martin Svaton. Guests: Marie Drösslerová, MD Clinical Oncologist and Pulmonologist, Department of Pulmonology, First Faculty of Medicine Charles University/Thomayer University Hospital, Prague Fernando Casas Mendez, MD Pulmonologist, Center for Thoracic Oncology and Surgery & National Oncology Center University Hospital Motol and Homolka, Prague Martin Svaton, Ph.D. Department of Pneumology and Phtiseology University Hospital in Pilsen

Kankakee resident Ray Balkcom was experiencing chest tightness on Thanksgiving Day. After receiving stents, doctors found a spot on his lung. Immediately referred to Riverside Cancer Institute, Ray and his team of providers developed a treatment plan specific to his journey.

Facing radical surgery 300km from home, Gillian Ryan tells PJ we need to shatter the myth that lung cancer is purely a smoker's disease and start a screening program. Her sister, Dawn, has set up a GoFundMe to help with the financial costs of recovery here Hosted on Acast. See acast.com/privacy for more information.

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM For patients who smoke or have a history of smoking, seeking lung cancer screening can mean confronting more than the fear of a diagnosis; it can also mean anticipating blame and judgment. Dr. Lisa Carter-Bawa joins us to share how tobacco-related stigma and nihilism can discourage screening, honest conversations, and follow-up care. Learn how approaching patients with greater awareness and compassion can help create a more supportive path to early detection. Dr. Carter-Bawa is the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation and a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She spoke about this topic at the 2026 World Conference on Lung Cancer.

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM Even well-intentioned conversations about tobacco use can leave patients feeling judged and potentially less willing to engage in lung cancer screening, follow-up, or cessation support. Tune in as Dr. Lisa Carter-Bawa shares practical strategies for fostering more supportive, patient-centered conversations that reduce stigma and keep the door open to screening and continued care. In addition to being the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery & Innovation, she's also a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She also spoke about this topic at the 2026 World Conference on Lung Cancer.

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM Even well-intentioned conversations about tobacco use can leave patients feeling judged and potentially less willing to engage in lung cancer screening, follow-up, or cessation support. Tune in as Dr. Lisa Carter-Bawa shares practical strategies for fostering more supportive, patient-centered conversations that reduce stigma and keep the door open to screening and continued care. In addition to being the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery & Innovation, she's also a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She also spoke about this topic at the 2026 World Conference on Lung Cancer.

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM For patients who smoke or have a history of smoking, seeking lung cancer screening can mean confronting more than the fear of a diagnosis; it can also mean anticipating blame and judgment. Dr. Lisa Carter-Bawa joins us to share how tobacco-related stigma and nihilism can discourage screening, honest conversations, and follow-up care. Learn how approaching patients with greater awareness and compassion can help create a more supportive path to early detection. Dr. Carter-Bawa is the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation and a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She spoke about this topic at the 2026 World Conference on Lung Cancer.

This week's podcast discusses a recent meta-analysis on the benefit of a "neutropenic diet" in patients on treatment for cancer. Link: https://doi.org/10.1200/OP-26-00405 The 2026 World Conference on Lung Cancer just wrapped up. We run through the findings of the most notable trials presented at WCLC. Download the Learning Oncology Companion:https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about breakthrough advances in thoracic oncology presented at the conference with Dr. Jorge Alatorre Alexander and Dr. Miguel Gonzalez Velez. Guests: Jorge Alatorre Alexander, MD Head of the Medical Oncology Service National Institute of Respiratory Diseases (INER) Miguel Gonzalez Velez, MD Medical Oncologist John Theurer Cancer Center at Hackensack University Medical Center

The 2026 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about breakthrough advances in thoracic oncology presented at the conference with Dr. Lilian Faroni and Dr. Vladmir Cordeiro de Lima. Guests: Lilian Faroni, MD, PhD Radiation Oncologist Oncologia D'Or Rio de Janeiro, Brazil Vladmir Cordeiro de Lima, MD, PhD Thoracic and Breast Oncologist A.C. Camargo Cancer Center, São Paulo, Brazil

The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched another late-stage trial win for its LSD drug, and Novartis continues to reel from the company's triple asset stumble.

While most people are familiar with HER2 in regards to breast cancer,  there are HER2 mutations in lung cancer. On this episode of the ATS Breathe Easy podcast, host Patti Tripathi explores HER2-mutant non-small cell lung cancer (NSCLC), an uncommon but increasingly treatable form of lung cancer. Oncologist Christine Lovly, MD, PhD, City of Hope, explains the rapidly evolving science behind HER2 testing and targeted therapies, while patient Nicole Field shares her experience living with stage IV HER2-mutant lung cancer.For more resources, check out these organizations:LUNGevity Foundation: https://www.lungevity.org/International Cancer Advocacy Network: https://askican.org/Rexanna's Foundation: https://rexannasfoundation.org/

The 2026 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about breakthrough advances in thoracic oncology presented at the conference with Dr. Zhengfei Zhu, Dr. Yun Fan, and Dr. Dongsheng Yue. Guests: Dr. Yun Fan, MD, PhD Chief Expert of the Multidisciplinary Lung Cancer Team, Zhejiang Cancer Hospital; Senior Consultant (Grade II Chief Physician); Doctoral Supervisor Dr. Dongsheng Yue, MD, PhD Tianjin Medical University Cancer Institute and Hospital Dr. Zhengfei Zhu, MD, PhD Department of Radiation Oncology Fudan University Shanghai Cancer Center

Our guest today is someone whose work touches almost every corner of oncology: from the exam room to the lab to the systems we work within.Dr Narjust Florez, MD, FASCO, is a thoracic medical oncologist at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, where she treats young patients and women with lung cancer and leads a research program spanning early diagnosis, clinical trials, and cancer health disparities. She's the Associate Director of the Cancer Care Equity Program and leads the EQUAL Study, which tackles disparities in lung cancer screening among Hispanic and East Asian patients. She's also become one of the most influential voices on physician wellness and burnout in oncology, and on building a more equitable path for women and underrepresented trainees in the field — work that's earned her recognition as the youngest Fellow ever named to the Association for Clinical Oncology, and a spot as JAMA Oncology's first Latina Associate Editor for Diversity, Equity, and Inclusion.Please welcome Dr Narjust Florez.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners, Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Send us Fan MailMorning Prayers (Praise; God our Refuge; Forgiveness; Body of Christ; Pastors / Families; Lung Cancer; Knee & Joint Pain; Human Trafficking; Friends Praying With Me; Straight Paths)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

When Steve Harrison experienced fatigue, back soreness and shoulder pain in 2024, he attributed it to his "getting old."  He was in his early fifties.  But when he began to have difficulty breathing, he sought medical attention.  Because Steve also had asthma, his doctor had COPD, she prescribed an inhaler.  That did little to no good.  He saw another doctor who ran a variety of tests, which found pleural fusion.  After a bronchoscopy and a biopsy, he was diagnosed with Stage IV lung cancer.  In addition to chemotherapy, the oncologist prescribed a TKI inhibitor, known as tagrisso.  After nine treatments, he was taken off chemo, but remains on tagrisso, which is not a cure, but a treatment, and has allowed Steve to get on with his life.  He would say his health is roughly 70-80 percent of what it was, pre-diagnosis.   Steve's San Diego job as a construction inspector was physically stressful.  That's why when was getting tired more often than usual, when he had back and shoulder pain, he did not immediately seek medical attention because he thought it was part of getting old.  But things went from bad to worse.  In addition to having shortness of breath, he began to get night sweats.  He thought he could address these issues with Tylenol and Theraflu.    He finally went to his primary care doctor who listened to his chest, thought he had COPD and gave him an inhaler.  That worked for one day, then didn't work at all.  On a visit to the Grand Canyon, the 6,000-foot elevation really made it tough for him to breath.  In addition, he was constantly tired and sore all over.  Upon returning to San Diego, he went to the emergency room.   Steve underwent a variety of tests.  Doctors found pleural fusion, which is fluid inside the lung.  They said the fluid needed to be removed.  A thoracentesis was performed, which removed about 400cc of a yellowish fluid.  Once it was out, Steve could breathe again.  Then he underwent another test, a biopsy.  It indicated Steve had metastatic Stage IV lung cancer, which had metastasized from the base of his skull to his spine.   The cause of the cancer was a mutation, EGFR exon 19 deletion.  The oncologist prescribed a two-pronged chemotherapy regimen of carboplatin and pemetrexed for the lung and for the mutation, a TKI inhibitor known as tagrisso.    Steve suffered the side effects generally associated with chemotherapy.  During his nine treatments, he experienced fatigue, cognitive issues and food tasted terrible.  His oncologist eventually took him off the chemo, kept him on the tagrisso.   The bone lesions eventually disappeared, and Steve's health has returned to about 70-80 percent of what it was before his diagnosis.  Steve says the tagrisso is not a cure, but does keep his lung cancer at bay.   By way of advice, he says science has come a long way, so much so that a diagnosis of metastatic Stage IV lung cancer should not be considered a death sentence.  He also urges anyone diagnosed with the disease to "dive deep" and stay mentally strong even when it seems that is very hard to do.   Additional Resources:   Support Group:   The A Breath of Hope Lung Foundation  https://www.abreathofhope.org   Steve's YouTube channel  EFGRandme      

Michael A. Crane, the medical director of the World Trade Center Health Program Clinical Center of Excellence at Mount Sinai, thought he would be seeing a lot of cases of lung cancer coming into his clinic. “My greatest concern was that they were gonna get lung cancer,” Crane said. He remembers treating 9/11 first responders during the immediate recovery. Workers would put on a mask and the filter would clog up within 30 minutes. The air was thick and impossible to breathe. But 25 years later, an uptick in lung cancer hasn't really panned out in the data—so far. “Fingers crossed, fingers crossed, it might be off the table,” he said. “But of course, there's no guarantees in life, as in anything else.”In this episode of the Cancer History Project podcast, reporter Sara Willa Ernst sits down with Michael Crane to talk about the surprising twists and turns of treating 9/11 first responders over the past 25 years. He also offers his theory behind why the incidence of lung cancer didn't spike as expected—an achievement, perhaps one of Crane's proudest, that the program was able to accomplish. The WTC Health Program was able to reduce smoking among first responders from 20% to just 3%, according to Mount Sinai data.“When I die, and God asks me: ‘What did you do with your life?' I'm gonna give them that statistic and demand to get into the doors. ‘Open the doors, buddy! Look what I did here,'” Crane said. The Cancer History Project Podcast is sponsored by City of Hope, the American Society of Clinical Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center. A transcript of this podcast is available, along with an archive of related articles, on the Cancer History Project website:  https://cancerhistoryproject.com/article/michael-crane-911/ 

Read the full article here: https://oncdata.com/personalizing-surgical-risk-assessment-in-lung-cancer For many patients with lung cancer, surgery offers the best chance for cure and long-term survival, but that opportunity can come with meaningful risk—particularly for older patients with smoking histories, reduced lung function, frailty, or other medical conditions. In this episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Dr. Kenneth Patrick Seastedt, Thoracic Surgeon at Roswell Park Comprehensive Cancer Center, about MIRACLE, an AI-enabled platform designed to help predict postoperative pulmonary complications after lung cancer surgery. By combining clinical data, radiomic information extracted from CT imaging, and large language model (LLM)–generated risk explanations, the platform creates a more personalized assessment of surgical risk—all while keeping surgeons involved in every stage of interpretation and decision making.

Solange Peters, Lizza Hendricks, and Martin Reck join Jonathan Blott to discuss The Lancet Respiratory Medicine Series on therapeutics in lung cancer, published to coincide with the Series launch at ERS 2026. The Series reviews developments in the treatment of non-small-cell lung cancer, from emerging approaches in early-stage disease to targeted therapies for advanced disease. The authors discuss the evidence supporting existing treatment strategies, areas of uncertainty in clinical practice, new and emerging biomarkers, and priorities for further research. Click here to read the full series: https://doi.org/10.1016/ S2213-2600(26)00221-3 https://doi.org/10.1016/ S2213-2600(26)00253-5

Grace Kelley of Vogelzang Law joins Jon Hansen on Let's Get Legal to discuss legal representation for individuals affected by asbestos exposure. Grace talks about the most difficult parts of a case, negligent companies, and the fact that asbestos is still present in homes and job sites. For more info, call 312.466.1669 or visit vogelzanglaw.com.

Our medical experts break down the month's biggest health news from new insights into how ADHD presents in women to an increase in lung cancer among nonsmokers. Then, our panel of doctors answers your questions.

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

In this episode, Dr. Narjust Florez is joined by Dr. Yasir Elamin and Dr. Liliana Faroni to explore the evolving management of oligometastatic lung cancer. They break down key definitions, discuss when and how to use consolidative therapies like radiation and surgery, and examine patient selection, limitations, and emerging tools such as ctDNA that are shaping a more precise approach to care. Guests: Yasir Elamin, MD Associate Professor of Thoracic Medical University of Texas MD Anderson Cancer Center Liliana Faroni, MD, PhD Radiation Oncologist, Oncologia D'Or Rio de Janeiro

Dr. Eric Winer and Dr. Anne Chiang talk about advancements in lung cancers and the need for more screening and early detection. Visit: https://medicine.yale.edu/cancer/ Email: canceranswers@yale.edu Call 203-785-4095

In this Korean-language episode of Lung Cancer Considered, Dr. Chul Kim is joined by Dr. Hye-Ryun Kim and Dr. Young Kwang Chae to discuss the evolving role of immunotherapy across the lung cancer treatment continuum. They explore perioperative strategies for resectable NSCLC, treatment selection and biomarkers in advanced disease, emerging research, and what they are looking forward to at WCLC 2026 in Seoul. Guest Host: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Guests: Hye Ryun Kim, MD, PhD Medical Oncologist Chief of Lung Cancer Center Yonsei Cancer Center Young Kwang Chae, MD, MPH, MBA Professor, Division of Hematology Oncology, Department of Medicine Northwestern University Feinberg School of Medicine

In this episode, Dr. Paul Wheatley-Price sits down with Patricia and Jim Leong, competitive figure skaters who have represented Canada on the national and international stage, along with Dr. Kirsten Perdrizet, Medical Oncologist at William Osler Health System, for a candid conversation about living with and treating RET-fusion lung cancer. Patricia and Jim share their experience navigating Patricia's diagnosis and treatment together, and how it's affected their everyday lives and time on the ice. Meanwhile, Dr. Perdrizet helps break down what RET+ lung cancer is, who it affects, and how treatment decisions are made, from first-line therapy to options later in the treatment journey.

SHOWNOTES Apple Podcast Description: Episode Title: In this episode of All Talk Oncology, host Kenny Perkins (Your Cancer Guy) talks with Dr. Jeffrey Velotta, a thoracic surgeon practicing in Northern California, to discuss a growing and often misunderstood health crisis—lung cancer in people who have never smoked. While many people associate lung cancer primarily with smoking, Dr. Velotta explains that an alarming trend is emerging, particularly among Asian women who have never smoked. Despite California having one of the lowest smoking rates in the United States, the state continues to see some of the highest lung cancer incidence and mortality rates. Dr. Velotta breaks down the surprising risk factors behind this phenomenon, why many patients are being diagnosed at Stage IV, and what individuals can do to advocate for themselves when symptoms appear. This conversation is an essential listen for patients, caregivers, and anyone concerned about lung health—especially those who believe they are not at risk. In this episode, Dr. Castro discusses: Why lung cancer is increasing among non-smokers The alarming rise of lung cancer in Asian women Why many patients are diagnosed at Stage IV Key risk factors beyond smoking The importance of early detection and recognizing symptoms Why persistent cough should never be ignored When to request a chest X-ray or CT scan Why getting a second opinion is critical for cancer care How patients can find clinical trials and new treatment options Dr. Velotta also encourages patients to become active participants in their healthcare by asking tough questions, advocating for themselves, and seeking the best possible care. This episode provides vital insight into a growing public health issue and empowers patients with the knowledge needed to take action early. Don't forget to like, subscribe, and share to help spread awareness about lung cancer and empower patients with life-saving information. Immortalize your voice by being an ALL TALK ONCOLOGY GUEST! Just fill-out this FORM. Invite Kenny Perkins to Speak or Participate on your event. Just fill-out this FORM.   SOCIAL MEDIA LINKS: All Talk Oncology: Instagram & Facebook JOIN OUR FREE COMMUNITY: Facebook Community WEBSITE: www.alltalkoncology.com Hashtags:  #LungCancerAwareness #LungCancerInNonSmokers #ThoracicSurgery #CancerScreening #AllTalkOncology #YourCancerGuy #CancerEducation #CancerAdvocacy

Host Dr. Stephen Liu is joined by José Luis Castro, WHO Director-General Special Envoy for Chronic Respiratory Diseases, for a thought-provoking discussion on why lung cancer must be recognized as a global health priority. They explore the challenges of raising awareness, reducing stigma, expanding equitable access to lung cancer screening and care, and advancing the policies and partnerships needed to improve outcomes worldwide. The conversation also offers a preview of Castro's keynote message ahead of his appearance at the 2026 World Conference on Lung Cancer (WCLC) in Seoul this September. Guest: José Luis Castro World Health Organization (WHO) Director-General Special Envoy for Chronic Respiratory Diseases

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of updates that underscore the dynamism and complexity of these industries, marked by breakthroughs, strategic shifts, and regulatory hurdles. A notable scientific advancement comes from Biokin Pharma, where their bispecific antibody-drug conjugate, Iza-Bren, has achieved its primary endpoint in a Phase 3 trial focused on lung cancer. This success underscores the promise of ADCs in oncology, particularly their ability to target cancer cells while minimizing damage to healthy tissues. This approach not only enhances the efficacy of cancer therapies but also reduces side effects, providing a compelling argument for Bristol Myers Squibb's global testing initiatives in this domain. Such advancements are pivotal as they represent a significant leap toward more personalized cancer treatments. In regulatory and corporate news, Sanofi's recent restructuring following its acquisition of Blueprint Medicines has been significant. The integration process involves laying off 229 employees and closing operations in Cambridge. This move highlights a broader trend of consolidation within the biotech sector as companies seek to streamline operations and optimize resources amid an increasingly competitive market. Meanwhile, CSL Behring, an Australian company specializing in plasma and vaccines, anticipates mid-single-digit growth by fiscal year 2027. This optimistic outlook follows a period of challenges, including impairments and leadership changes. The company attributes its recovery largely to advancements in immunoglobulin therapies, which play a critical role in treating immune deficiencies and autoimmune diseases, highlighting the importance of innovation in sustaining growth. On the clinical trial front, Amylyx Pharmaceuticals is making waves with its GLP-1 receptor antagonist Avexitide. The drug has shown promising Phase 3 results by significantly reducing hypoglycemic episodes in patients with a rare endocrine disorder. This finding could revolutionize treatment protocols for endocrine disorders beyond traditional diabetes management, emphasizing the potential of GLP-1 inhibitors to enhance patient outcomes across various conditions. The latest updates from Amylyx Pharmaceuticals further showcase these industry dynamics as they prepare for an FDA filing for Avexitide following successful trial outcomes. The drug addresses post-bariatric hypoglycemia—a critical gap in metabolic disorder management—highlighting its potential impact on patient care and market dynamics with an anticipated $1.7 billion peak sales forecast. However, not all developments have been positive. EyePoint Pharmaceuticals faced setbacks with Duravyu, their AMD drug-device combo, which did not meet expectations in a Phase 3 trial. This highlights the inherent risks of developing drug-device combinations in late-stage trials and underscores the competitive pressures from market leaders like Eylea. In another strategic shift within big pharma, Merck KGaA has laid off 20 staff members from its U.S. research team as part of an ongoing reassessment of research priorities and resource allocations. Similarly, BioMarin Pharmaceutical's $275 million acquisition of Alesta Therapeutics marks an effort to bolster their bone disease portfolio and challenge competitors like AstraZeneca in specialized therapeutic areas. BioMarin's acquisition emphasizes competition within rare diseases—a sector ripe with opportunities for innovative treatments addressing unmet needs. Technological advancements are also reshaping the landscape. Johnson & Johnson MedTech's recent software updates for its Monarch bronchoscopy robot illustrate how digital solutions are enhancing diagnostic capabilities in lung cancer detection. This aligns with industry trends towards leveraging AI and robotics to improve precision medicine. Eurofins CDMO Alphora's expansion to meet the growing demand for high-potency active pharmaceutical ingredients reflects a rising interest in targeted therapies requiring precise dosing and specialized manufacturing processes. Such trends indicate a shift toward more personalized medicine approaches that prioritize efficacy and safety. Despite setbacks faced by companies like Regeneron due to safety concerns halting clinical trials, strategic moves such as GSK's licensing agreement with Chugai Pharmaceutical for an anti-dengue antibody exemplify ongoing efforts to combat infectious diseases through innovative biologics. The collaboration between Evaxion and Duke University on AI-designed glioblastoma vaccines further illustrates how artificial intelligence is becoming integral to next-generation cancer therapies—potentially paving the way for personalized vaccines that optimize antigen selection based on individual tumor profiles. Rigel Pharmaceuticals' launch of Veppanu marks another milestone—the first FDA-approved PROTAC for advanced breast cancer—demonstrating novel mechanisms targeting pathogenic proteins effectively while offering new treatment avenues for molecularly defined cancers. These stories capture the essence of today's pharmaceutical landscape: one where innovation coexists with challenges but holds immense potential to transform healthcare delivery globally. As companies continue pushing boundaries with emerging technologies like AI integration or expanding into niche markets through strategic acquisitions—the future looks promising for delivering more targeted solutions tailored toward specific patient populations worldwide.Support the show

This week, Bobbi Conner talks with MUSC's Dr. Gerard Silvestri about research indicating that many advanced lung cancer patients never receive treatment.

Joanna Nathan, CEO and co-founder of Prana Surgical, adjunct professor at Rice University and a former MedTech investor who spent years at the J&J MedTech Center for Device Innovation before crossing over into building herself. Her company recently secured FDA clearance for the Prana System, a tissue-sparing platform rethinking how early stage lung cancer is diagnosed and treated.In this episode, Joanna shares the deeply personal story behind her move from investing back into operating, having lost her four year old son in 2021 and wanting proximity to patient impact rather than evaluating innovation from the sidelines. It is an honest and moving conversation about what actually drives someone to take on a decade-long mission.We get into what she learned watching hundreds of pitches from the investor seat, why a no is very often about portfolio construction and timing rather than the quality of your idea, and why a fundraising pitch is a vision document backed by evidence rather than a journal article. Joanna then breaks down the problem Prana is solving, why removing large portions of lung for a tiny early stage nodule is no longer justifiable and how the system is right-sized for the level of risk these smaller lesions present.We also explore the changing face of lung cancer, the rise of never smokers now approaching one in three patients, why the disease is getting younger and more female, the role of mobile screening in rural areas and where AI genuinely helps rather than replaces clinical judgement. Joanna closes with hard-won advice for anyone thinking about founding a company and why community is what carries you through.Timestamps[00:01:38] From Research to Investing to Building: The Path Back to Operating[00:03:33] Why a No From an Investor Is Rarely About Your Idea[00:05:29] Why a Pitch Is a Vision Document Not a Journal Article[00:07:16] The Problem With Early Stage Lung Cancer Surgery Today[00:09:22] The Rise of Never Smokers and a Disease That Is Changing Fast[00:11:03] Why Women Under 50 Now Face Higher Lung Cancer Rates[00:13:18] Getting Creative on Access: Mobile CT Screening in Rural Areas[00:17:21] AI in MedTech: Assisting Clinical Judgement Not Replacing It[00:19:22] How Houston Became an Unlikely MedTech Powerhouse[00:24:06] Who Should Not Become a Founder and the Decade-Long QuestionConnect with Joanna - ⁠linkedin.com/in/joannacnathan/Learn more about Prana Surgical - https://www.pranasurgical.com/Get in touch with Karandeep Badwal - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/karandeepbadwal/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Karandeep on YouTube - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@KarandeepBadwal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medical device training courses delivered by Karandeep through Bywater - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.bywater.co.uk/

Shira Boehler's family is full of doctors, and every one of them told her not to get the full-body MRI. She canceled the appointment repeatedly herself, until her husband rebooked it one time too many and she finally went.The scan found a 3.8 centimeter mass in her right lung and labeled it a minor finding, with a note to correlate with symptoms. She had none. She was running six miles a day, the picture of health, and had never smoked. A follow-up CT months later showed the mass had grown, and on the Monday she walked into a pulmonary specialist's office she was told she had an invasive adenocarcinoma. She told him it was probably an EMR error. One week later, surgeons removed half her right lung to treat her cancer.Samira Daswani, host of Patient from Hell and founder of Manta Cares, welcomes lung cancer survivor and bestselling author Shira Boehler for an eye-opening conversation on the part that comes after the story, which is why almost nobody in Shira's position gets caught this early. Screening guidelines currently cover people over 50 with a twenty-pack-per-year smoking history, and fewer than one in five of them actually get scanned, in part because the criteria require disclosing something patients are ashamed of. Shira has been working the problem from both ends since her treatment, negotiating cash prices at imaging centers down to a fraction of what she paid and funding new scans for people who can't cover them through the nonprofit organization she founded, Cancer Doesn't Care.In this episode, Samira and Shira discuss:Why lung cancer is often diagnosed too lateThe importance of early detection and low-dose CT screeningHow people who have never smoked can still develop lung cancerThe stigma surrounding lung cancer diagnosisCurrent lung cancer screening guidelinesInsurance coverage, healthcare access, policy reformHow artificial intelligence may improve cancer screeningWhy patient advocacy is becoming increasingly important in modern healthcareChapters00:00 Introduction01:00 The Full-Body Scan That Changed Everything03:32 Diagnosed With Lung Cancer Despite Having No Symptoms05:30 Access, Privilege & Why Early Detection Isn't Equal07:10 Building the Cancer Doesn't Care Foundation09:21 Why Lung Cancer Screening Needs to Change10:19 Breaking the Stigma Around Lung Cancer12:26 Who Actually Qualifies for Screening?14:23 Changing Public Perception Through Advocacy16:20 Why Patients Must Advocate for Themselves17:15 AI, False Positives & the Future of Cancer Screening20:27 Why Lung Cancer Is Often Diagnosed Too Late21:17 Stage 1 vs. Stage 4 Survival Rates23:25 Shira's Advice for Anyone Considering Lung Cancer ScreeningShira Kupperman Boehler is a finance professional, health advocate, bestselling author, and lung cancer survivor. Shira holds a degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from New York University's Stern School of Business. Alongside her husband Adam, she has spent her career building and scaling multibillion-dollar healthcare businesses, developing deep relationships across health systems, payers, and policymakers.After being unexpectedly diagnosed with Stage 1B lung adenocarcinoma despite never smoking and having no symptoms, Shira founded Cancer Doesn't Care, a nonprofit dedicated to expanding access to life-saving lung cancer screening and reducing financial barriers to early detection. She is also the author of the bestselling memoir One Scan Saved My Life, with proceeds supporting patient screening initiatives.

In this episode of the STS Thinking Thoracic podcast, host Dr. Jeff Yang is joined by thoracic surgeons Dr. Seth Krantz and Dr. Christopher Seder, along with Harvard medical student Alexandra Potter, to discuss three landmark studies using the STS General Thoracic Surgery Database that are reshaping how lymph node evaluation is performed in lung cancer surgery. The panel explores current guidelines, quality standards, and how more comprehensive nodal evaluation can improve staging accuracy while maintaining patient safety. The discussion highlights national trends in surgical quality, the importance of surgeon-pathologist collaboration, and the future of personalized lymph node evaluation, including the potential role of emerging technologies such as radiomics, genomic markers, and AI.

This clip comes from Dr. Raj's series with My Care Friends. Watch the video here: https://youtu.be/IsnRE6EAygw?si=V0-HJYdIPYNccXC9 About Dr. Raj Dr. Raj Dasgupta is an ABIM Quadruple board-certified physician specializing in internal medicine, pulmonology, critical care, and sleep medicine. He is currently the Associate Program Director of Internal Medicine Residency at Huntington Health in Pasadena, California and an Associate Professor of Clinical Medicine for the University of California, Riverside School of Medicine (UCR). He previously practiced at the University of Southern California, where he is an associate professor of clinical medicine, assistant program director of the Internal Medicine Residency Program, and the associate program director of the Sleep Medicine Fellowship. Dr. Dasgupta is an active clinical researcher and has been teaching around the world for more than 20 years. More from Dr. Raj ⁠⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠⁠ ⁠⁠⁠⁠Dr. Raj on Twitter⁠⁠⁠⁠ ⁠⁠⁠⁠Dr. Raj on Instagram⁠⁠⁠⁠ Want more board review content? ⁠⁠⁠⁠USMLE Step 1 Ad-Free Bundle⁠⁠⁠⁠ ⁠⁠⁠⁠Crush Step 1⁠⁠⁠⁠ ⁠⁠⁠⁠Step 2 Secrets⁠⁠⁠⁠ ⁠⁠⁠⁠Beyond the Pearls⁠⁠⁠⁠ ⁠⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠⁠ ⁠⁠⁠⁠Beyond the Pearls Premium⁠⁠⁠⁠ ⁠⁠⁠⁠USMLE Step 3 Review⁠⁠⁠⁠ ⁠⁠⁠⁠MedPrepTGo Step 1 Questions⁠⁠⁠⁠ ⁠⁠⁠⁠MedPrepTGo Step 2 Questions⁠⁠⁠⁠ Follow MedPrepToGo ⁠⁠⁠⁠https://medpreptogo.com⁠⁠⁠⁠ ⁠⁠⁠⁠https://www.instagram.com/medpreptogo/⁠⁠⁠⁠ ⁠⁠⁠⁠https://www.linkedin.com/company/medpreptogo/⁠⁠⁠⁠ ⁠⁠⁠⁠https://www.facebook.com/MedPrepToGo/⁠⁠⁠⁠ ⁠⁠⁠⁠https://www.youtube.com/@MedPrepToGo⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma. The episode covers GSK’s first lung cancer approval following its acquisition of Nuvalent, Axiom Biosciences’ unusual plan to list first in Hong Kong before pursuing a Nasdaq co-listing amid a resurgent biotech IPO market, and the U.S. House’s passage of legislation directing the FDA to update its animal testing rules. The episode also includes an update from the Fierce newsroom, including the arrival of a new Fierce Biotech staff writer, and a reflection on why human judgment, curiosity and original reporting matter more than ever. To learn more about the topics in this episode: GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong House passes bill directing FDA to update animal testing rules See omnystudio.com/listener for privacy information.

This episode is dedicated to Natalie's memory and to every patient navigating life with cancer.Natalie Brown's answer to "How are you?" was always simple:"I'm here."Diagnosed with stage 4 non-small cell lung cancer at just 33 years old, despite never smoking and having no family history of lung cancer, Natalie spent six years challenging assumptions about what lung cancer looks like.In this unforgettable conversation with host Samira Daswani, Natalie shares her journey through multiple rounds of chemotherapy, immunotherapy, failed clinical trials, and one of the rarest procedures in cancer medicine a bilateral double lung transplant. She also opens up about recurrence, chronic pain, advocacy, mental health, and why she believed every patient deserves to know all of their treatment options.Natalie has passed away. We are honored to share her story again in celebration of the courage, honesty, humor, and determination that defined her life. Her voice continues to educate, inspire, and advocate for patients everywhere.Whether you're living with cancer, supporting someone who is, or simply want to better understand the realities of serious illness, Natalie's message is one everyone should hear.In this episode you'll learn:What it's like to be diagnosed with stage 4 lung cancer at age 33Why non-smokers can develop lung cancerHow a rare double lung transplant became a treatment optionThe emotional reality of cancer recurrenceClinical trials, targeted therapies, and asking "What's next?"The importance of patient advocacy and second opinionsHow friends, family, therapy, and hope helped Natalie keep fightingWhy "Anyone with lungs can get lung cancer"Natalie's story reminds us that resilience isn't about pretending things aren't difficult—it's about continuing to move forward anyway.00:00 Introduction: Remembering Natalie Brown01:00 "I'm Here" — The phrase that defined Natalie02:00 Diagnosed with Stage 4 Lung Cancer at 3304:00 Four Chemotherapies & Failed Clinical Trials05:30 Discovering a Rare Double Lung Transplant10:40 Returning Home After Transplant11:45 Cancer Recurrence & New Treatment Options13:00 The Husband Who Helped Her Keep Fighting16:00 Facing Mortality with Honesty18:00 Making the Most of Time20:00 Living with Chronic Pain21:00 Becoming a Lung Cancer Advocate24:00 Learning to Ask for Help26:45 Advice for Newly Diagnosed Patients28:40 "Anyone With Lungs Can Get Lung Cancer"29:45 Why Patients Should Always Ask Questions31:00 Final ReflectionsAbout Patient From HellPatient From Hell is hosted by cancer survivor and founder Samira Daswani, who asks the questions most patients are too overwhelmed or too afraid to ask. The show brings together doctors, researchers, advocates, and survivors to reveal evidence-based answers for patients navigating the chaos of cancer.

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology. Key Topics Covered: • ALK-positive lung cancer • Cellular Therapy • Vaccines Guests: Vincent Lam, MD Associate Professor of Oncology, Johns Hopkins University School of Medicine Director, Thoracic Oncology Clinical Research Program Sidney Kimmel Comprehensive Cancer Center Carmen Mecca. PhD Postdoctoral Fellow, Chiarle Lab Department of Pathology Boston Children's Hospital

Jonathan Villena-Vargas, MD, sits down with Erin Gillaspie, MD, to examine key findings from the American Society of Clinical Oncology (ASCO) Annual Meeting, including advances in targeted therapy, dual-pathway immunotherapy, artificial intelligence, and adaptive treatment strategies that are reshaping thoracic oncology.

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from July 3-10, 2026.

Join Dr. Martin in today's episode of The Doctor Is In Podcast.  

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (2:07) Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23) Currently Available ADCs for Gynecologic Cancer Management (26:37) Currently Available ADCs for Lung Cancer Management (44:07) Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55) Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07) Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01) NCPD information and select publications  

In this episode, we review the high-yield topic of ⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lung Cancer⁠⁠⁠⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Should you stop taking glucosamine based on a new study linking it to Alzheimer's? What's behind the spate of “Tai Chi Walking” social media posts? Undereye “festoons”—what to do about them? Are antibiotics the only treatment for SIBO? Vaping after smoking hikes risk for lung cancer.